Rasburicasa versus alopurinol como tratamiento de la hiperuricemia en el síndrome de lisis tumoral

This study demonstrated that there is more rapid control and lower plasma uric acid levels in patients at high risk for tumour lysis syndrome who received rasburicase compared to allopurinol, as well as lower levels of creatinine and a lower percentage of haemodialysis.